After finishing at $21.53 in the prior trading day, Myriad Genetics, Inc. (NASDAQ: MYGN) closed at $21.32, down -0.98%. In other words, the price has decreased by -$0.21 from its previous closing price. On the day, 586513 shares were traded.
Ratios:
Our goal is to gain a better understanding of MYGN by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.87 and its Current Ratio is at 2.01. In the meantime, Its Debt-to-Equity ratio is 0.19 whereas as Long-Term Debt/Eq ratio is at 0.17.
On December 19, 2023, Wells Fargo started tracking the stock assigning a Equal Weight rating and target price of $20.
On December 14, 2023, Guggenheim started tracking the stock assigning a Buy rating and target price of $23.Guggenheim initiated its Buy rating on December 14, 2023, with a $23 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 01 ’23 when Riggsbee Richard Bryan sold 30,000 shares for $19.09 per share. The transaction valued at 572,835 led to the insider holds 291,812 shares of the business.
Riggsbee Richard Bryan sold 30,000 shares of MYGN for $470,622 on Nov 01 ’23. The Chief Financial Officer now owns 321,812 shares after completing the transaction at $15.69 per share. On Jun 02 ’23, another insider, SPIEGELMAN DANIEL K, who serves as the Director of the company, sold 8,638 shares for $23.01 each. As a result, the insider received 198,760 and left with 40,493 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MYGN now has a Market Capitalization of 1.92B and an Enterprise Value of 1.93B. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.54 while its Price-to-Book (P/B) ratio in mrq is 2.45. Its current Enterprise Value per Revenue stands at 2.56 whereas that against EBITDA is -9.77.
Stock Price History:
Over the past 52 weeks, MYGN has reached a high of $24.21, while it has fallen to a 52-week low of $13.82. The 50-Day Moving Average of the stock is 21.50, while the 200-Day Moving Average is calculated to be 19.56.
Shares Statistics:
The stock has traded on average 661.13K shares per day over the past 3-months and 622.57k shares per day over the last 10 days, according to various share statistics. A total of 89.90M shares are outstanding, with a floating share count of 86.16M. Insiders hold about 4.14% of the company’s shares, while institutions hold 100.47% stake in the company. Shares short for MYGN as of Feb 29, 2024 were 4M with a Short Ratio of 6.05, compared to 3.71M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 4.45% and a Short% of Float of 6.15%.
Earnings Estimates
Its stock is currently analyzed by 12 different market analysts. On average, analysts expect EPS of -$0.1 for the current quarter, with a high estimate of -$0.03 and a low estimate of -$0.18, while EPS last year was -$0.21. The consensus estimate for the next quarter is $0, with high estimates of $0.03 and low estimates of -$0.02.
Analysts are recommending an EPS of between $0.07 and -$0.02 for the fiscal current year, implying an average EPS of $0.02. EPS for the following year is $0.24, with 13 analysts recommending between $0.38 and $0.03.
Revenue Estimates
12 analysts predict $193.26M in revenue for the current quarter. It ranges from a high estimate of $196.32M to a low estimate of $190.36M. As of the current estimate, Myriad Genetics, Inc.’s year-ago sales were $181.2M, an estimated increase of 6.70% from the year-ago figure.
A total of 13 analysts have provided revenue estimates for MYGN’s current fiscal year. The highest revenue estimate was $833.2M, while the lowest revenue estimate was $810.15M, resulting in an average revenue estimate of $826.67M. In the same quarter a year ago, actual revenue was $753.2M, up 9.80% from the average estimate. Based on 13 analysts’ estimates, the company’s revenue will be $894.78M in the next fiscal year. The high estimate is $914.32M and the low estimate is $860.19M. The average revenue growth estimate for next year is up 8.20% from the average revenue estimate for this year.
